Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Raptiva Clear all
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Results available

Efalizumab to Treat Uveitis

NCT00280826
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Efalizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 19, 2026, 10:59 AM EDT
Completed No phase listed Observational

An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)

NCT00097240
View directory record Official record
Conditions
Psoriasis, Pregnancy
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

NCT00368654
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Raptiva
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 19, 2026, 10:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
efalizumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

NCT00034203
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
efalizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
52
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 10:59 AM EDT
Withdrawn Phase 2 Interventional

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

NCT00308204
View directory record Official record
Conditions
Discoid Lupus Erthematosus of the Scalp
Interventions
Raptiva
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 19, 2026, 10:59 AM EDT
Withdrawn Phase 1 Interventional

Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration

NCT00726466
View directory record Official record
Conditions
Age Related Macular Degeneration, AMD, CNV
Interventions
Efalizumab, Ranibizumab
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

NCT00115076
View directory record Official record
Conditions
Psoriasis
Interventions
Efalizumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 19, 2026, 10:59 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

NCT00608777
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Calcipotriene/betamethasone
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

NCT00501709
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Belatacept and Raptiva
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 19, 2026, 10:59 AM EDT
Withdrawn Phase 1 Interventional

Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study

NCT00676559
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Efalizumab, Ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 19, 2026, 10:59 AM EDT
Terminated Not applicable Interventional Results available

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids

NCT00489216
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
efalizumab
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 19, 2026, 10:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus

NCT00133107
View directory record Official record
Conditions
Lichen Planus, Oral
Interventions
efalizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 19, 2026, 10:59 AM EDT
Completed No phase listed Observational

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

NCT00096928
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
182
States / cities
Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Efalizumab for Eczema

NCT00146003
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Efalizumab treatment
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation Using Abatacept

NCT00276250
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Efalizumab, Abatacept, Belatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

NCT00134134
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
efalizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 19, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis

NCT00302445
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Efalizumab, Narrow Band Phototherapy
Drug · Device
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Louisville, Kentucky • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2007 · Synced Oct 19, 2026, 10:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

NCT00777400
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
Efalizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 19, 2026, 10:59 AM EDT